Abstract
Mood disorders have been discussed as being in relation to glial pathology. S100B is a calcium-binding protein, and a marker of glial dysfunctions. Although alterations in the S100B expression may play a role in various central nervous system diseases, there are no studies on the potential role of S100B in mood disorders in adolescents and young adults . In a prospective two-year follow-up study, peripheral levels of S100B were investigated in 79 adolescent/young adult patients (aged 14–24 years), diagnosed with mood disorders and compared with 31 healthy control subjects. A comprehensive clinical interview was conducted which focused on clinical symptoms and diagnosis change. The diagnosis was established and verified at each control visit. Serum S100B concentrations were determined. We detected: lower S100B levels in medicated patients, compared with those who were drug-free, and healthy controls; higher S100B levels in a depressed group with a family history of affective disorder; correlations between age and medication status; sex-dependent differences in S100B levels; and lack a of correlation between the severity of depressive or hypo/manic symptoms. The results of our study indicate that S100B might be a trait-dependent rather than a state-dependent marker. Due to the lack of such studies in the youth population, further research should be performed. A relatively small sample size, a lack of exact age-matched control group, a high drop-out rate.
Highlights
Mood disorders are associated with significant psychosocial impairment marked by changes in mood, energy, thinking, and behavior
Primary we investigated a possible correlation between the serum levels of S100B and study subjects
Based on the findings on glial pathology in mood disorders in adult p atients[17,18] in our study, we provided some research questions following our hypothesis: (1) there are any differences in baseline serum S100B levels between depressed, hypomanic patients and healthy controls (2) could baseline S100B levels be influenced by clinical factors (3) is there a change between baseline S100B concentrations and euthymic state and (4) do different baseline S100B levels predict diagnosis change from unipolar to bipolar disorder in young patients
Summary
Mood disorders are associated with significant psychosocial impairment marked by changes in mood, energy, thinking, and behavior. Based on the findings on glial pathology in mood disorders in adult p atients[17,18] in our study, we provided some research questions following our hypothesis: (1) there are any differences in baseline serum S100B levels between depressed, hypomanic patients and healthy controls (2) could baseline S100B levels be influenced by clinical factors (severity of depressive and manic symptoms, medication status, family history of psychiatric and affective disorders, or gender) (3) is there a change between baseline S100B concentrations and euthymic state (as well as in a 2-year follow-up) and (4) do different baseline S100B levels predict diagnosis change from unipolar to bipolar disorder in young patients
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
